Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion.

By T. Ma, J. R. Thiagarajah, Hong Yang, N. Sonawane, C. Folli, Luis J. V. Galietta, A. Verkman. Journal of Clinical Investigation, 2002

703 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Targeting virulence: a new paradigm for antimicrobial therapy (2007, background): “A screen for inhibitors of the cystic fibrosis transmembrane conductance regulator (CFTR) protei”
Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders (2017, methodology): “More important, we provide evidence showing that directly targeting NLRP3 itself by CY-09 could inhibit NLRP3 inflammasome activation in vivo and had remarkable therapeutic effects on the mouse models of NLRP3-driven diseases, such as T2D and CAPS. reSuLtS cY-09 specifically blocks nLrP3 activation ”
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 (2009, positive): “The effect of VX-770 on the PD and amiloride response were augmented by subsequent addition of forskolin and blocked by prior addition of CFTRinh-172 (Fig.”